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Abstract
Background/Aims: Systemic hyperlipidemia and intracellular lipid accumulation induced by
chronic high fat diet (HFD) leads to enhanced fatty acid oxidation (FAO) and ketogenesis.
The present study was aimed to determine whether activation of peroxisome proliferatoractivated receptor-γ (PPAR-γ) by surplus free fatty acids (FA) in hyperlipidemic condition,
has a positive feedback regulation over FAO and ketogenic enzymes controlling lipotoxicity
and cardiac apoptosis. Methods: 8 weeks old C57BL/6 wild type (WT) or PPAR-γ-/- mice were
challenged with 16 weeks 60% HFD to induce obesity mediated type 2 diabetes mellitus
(T2DM) and diabetic cardiomyopathy. Treatment course was followed by echocardiographic
measurements, glycemic and lipid profiling, immunoblot, qPCR and immunohistochemistry
(IHC) analysis of PPAR-γ and following mitochondrial metabolic enzymes 3-hydroxy-3methylglutaryl-CoA synthase (HMGCS2), mitochondrial β- hydroxy butyrate dehydrogenase
(BDH1) and pyruvate dehydrogenase kinase isoform 4 (PDK4). In vivo model was translated
in vitro, with neonatal rat cardiomyocytes (NRCM) treated with PPAR-γ agonist/antagonist
and PPAR-γ overexpression adenovirus in presence of palmitic acid (PA). Apoptosis was
determined in vivo from left ventricular heart by TUNEL assay and immunoblot analysis.
Results: We found exaggerated circulating ketone bodies production and expressions of the
related mitochondrial enzymes HMGCS2, BDH1 and PDK4 in HFD-induced diabetic hearts
and in PA-treated NRCM. As a mechanistic approach we found HFD mediated activation of
PPAR-γ is associated with the above-mentioned mitochondrial enzymes. HFD-fed PPAR-γ-/mice display decreased hyperglycemia, hyperlipidemia associated with increased insulin
responsiveness as compared to HFD-fed WT mice PPAR-γ-/--HFD mice demonstrated a
more robust functional recovery after diabetes induction, as well as significantly reduced
myocyte apoptosis and improved cardiac function. Conclusions: PPAR-γ has been described
Khadija Rafiq, PhD.

1020 locust street, JAH 543A, Center for Translational Medicine, Thomas Jefferson University
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previously to regulate lipid metabolism and adipogenesis. The present study suggests for the
first time that increased PPAR-γ expression by HFD is responsible for cardiac dysfunction via
upregulation of mitochondrial enzymes HMGCS2, BDH1 and PDK4. Targeting PPAR-γ and its
downstream mitochondrial enzymes will provide novel strategies in preventing metabolic and
myocardial dysfunction in diabetes mellitus.
© 2018 The Author(s)
Published by S. Karger AG, Basel

Introduction

Chronic HFD induction is associated with dysregulated glucose and lipid metabolism
and thus, overall dysregulated energy homeostasis [1-3]. Shifting in the energy balance is
the major cause for insulin resistance, obesity and T2DM. The overall prevalence of insulin
resistance and T2DM in developed societies is alarmingly high, afflicting 30% of American
adults and about 14% of the European adults [4-6]. The combination of obesity and T2DM
contributes significantly to the rise in cardiovascular diseases.
During HFD-mediated T2DM, lipids accumulate, FAO is enhanced, and cardiomyocyte
apoptosis subsequently occurs in a process collectively known as lipoapoptosis. This has
been proposed to play a significant role in the development of cardiovascular diseases [710]. However, the mechanisms that lead to diabetes-induced heart disease are complicated
and remain largely unknown [9]. Evidence supports an association between chronic
hyperlipidemia and morphological and functional changes in hearts. Many of these changes,
including cardiac hypertrophy and compromised left ventricular (LV) function, are believed
to be precursors of more exaggerated forms of cardiac dysfunction and heart failure [11-16].
The cardiac structural and functional changes result from a dramatic metabolic shift
that takes place in diabetic hearts: the hyperlipidemic environment impairs glucose
uptake by decreased expression and translocation of Glut4/Glut1 receptors. To compensate
for the decrease in glucose, FA metabolism becomes the major conduit of energy supply
to support cardiac functions. As a vicious cycle, increased myocardial FA intake makes the
cardiomyocytes to lose the ability to use glucose more, leading to cardiac metabolic inflexibility.
Dependence of heart muscle on FAO over glucose oxidation leads to hyperglycemia and
insulin resistance [17-19]. Studies have shown that during the development of T2DM and in
diabetic db/db mice, there is a decrease in glucose oxidation and an increase in reliance on
FAs [17, 20-22].
In diabetic heart, the characteristic disturbances in myocardial energy and FA
homeostasis are regulated by PPAR transcription factors by governing the expressions of key
proteins in FA metabolic pathways [23-27]. Activation of PPARs leads to an increase in free
FA uptake and oxidation, corresponding to the level of insulin resistance in cardiomyocytes
[20]. This exaggerated reliance on FA metabolism decreases the overall efficacy of the heart by
increasing the oxygen consumption to create the needed energy, resulting in lipotoxicity. The
FA-driven activation of PPAR transcription factors regulates the expression of target genes,
affecting uptake, oxidation, and storage of FAs [28]. Among the three isoforms exist, α, β/δ,
and γ, PPAR-γ is mostly activated by free FA and eicosanoids and predominantly expressed
in adipose tissues and, to a lesser extent, in other tissues including heart, regulating lipid
metabolism [29, 30].
For ATP production, the mitochondrial enzyme complex pyruvate dehydrogenase (PDH)
utilizes glycolytically-derived pyruvate, and cardiac PDH activity is mostly regulated by PDK4
(EC 2.7.11.2). The expression of PDK4 rapidly increases along with the increased availability
of FAs over glucose during the generation of HFD-mediated T2DM. This metabolic shift
causes diet-induced loss of mitochondrial pyruvate utilization and the ensuing development
of insulin resistance in the heart [31-40].
The high rate of FAO in T2DM patients increases production of high-energy phosphates,
acetyl CoA and NADH, which are converted to ketone bodies through ketogenesis. In diabetic
condition the ketone bodies serve as an important glucose- sparing fuel source [41, 42]. In
mitochondria, a series of ketogenic reactions are catalyzed by mitochondrial thiolases, among
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which mitochondrial HMGCS2 (EC 2.3.3.10) is the rate-limiting enzyme for ketogenesis that
converts acetyl CoA derived from β-oxidation of FAs to acetoacetate (AcAc) [43, 44]. The
AcAc in turn is reduced by BDH1 (EC 1.1.1.30) to β-hydroxy butyrate (βOHB) [42, 43]. We
recently showed that HMGCS2 was most upregulated gene in type I diabetic heart of mice
model which is also an indirect reflection of exaggerated HMGCS2 activity as the rate limiting
enzyme of this pathway [44]. Interestingly other previous findings showed HMGCS2 and
PDK4 genes are transcriptionally regulated by PPAR-γ via PPAR responsive element (PPRE)
and PPAR-γ coactivator 1 (PGC-1) [45, 46]. But there is no study found till date that provide
insight if PPAR-γ can regulate the activities of HMGCS2, BDH1 and PDK4 at protein levels and
if that differential regulation may have a potential effect on cardiac structure and function in
hyperlipidemic environment at long run.
Relying on these background evidences supported by our data, we demonstrate for the
first time that PPAR-γ being activated by high intracellular contents of free fatty acids in a
lipid rich environment induces the expressions of ketogenic enzymes HMGCS2, BDH1 and
PDK4, the regulatory enzyme for PDH complex. Also our data showed how upregulation
of the above mentioned enzymes are correlated with lipotoxicity and cardiac dysfunction.
Hence, we postulate that PPAR-γ antagonism may provide a novel therapeutic strategy for
preventing adverse effects from HFD mediated T2DM and cardiac abnormalities.
Materials and Methods

Animals and diet
C57BL/6 male mice, 8 weeks of age, were purchased from the Jackson Laboratory (Bar Harbor, Maine).
Mice were housed at Thomas Jefferson University animal facility under standard conditions (12/12 lightdark cycle, humidity at 50 ± 15%, temperature 22 ± 2°C). They were either fed with standard diet (13% kcal
from fat) or high fat diet (60% kcal from fat, Research diets, New Brunswick, NJ, cat. no. D12492) for 16
weeks [47]. Body weight, food intake, and blood glucose were recorded weekly. All animal protocols have
been approved by the Institutional Animal Care Committee of Thomas Jefferson University, and experiments
conformed to the Guide for the Care and Use of Laboratory Animals published by the U.S. National Institutes
of Health and approved by the American Physiological Society.
Rosa26-CreERT2-PPAR-γflox/flox mice were a generous gift from Dr. Richard Pestell, Blumberg Institute.
These mice were generated according to previous publication [48]. To induce Cre-dependent recombination,
tamoxifen (20 mg/kg body weight, Sigma- Aldrich) was injected into 6-weeks-old animals intraperitoneally
for 5 days [49]. Ubiquitous PPAR-γ deficiency was achieved 1 week after injection as verified by western
blot analysis. For easier reading, we refer to these mice as PPAR-γ-/- mice. They were paired with age- and
sex-matched PPAR-γWT/WT littermates for all experiments.
Genotyping of mice
The PPAR-γflox/flox and PPAR-γwt/wt alleles and the Cre transgene were detected in mouse tail DNA
by PCR. Primers for PPAR-γflox/flox and PPAR-γwt/wt result in a 285 bp and a 233 bp product, respectively.
The primer sets used are: Flox-PPAR-γ (Forward 5’- CTCCAATGTTCTCAAACTTAC -3’; Reverse, 5’GATGAGTCATGTAAGTTGACC -3’); Rosa26(Forward 5’- AAAGTCGCTCTGAGTTGTTAT -3’; Reverse 5’GGAGCGGGAGAAATGGATATG -3’), CRE-ER (5’- CCTGATCCTGGCAATTTCG-3’).
We labeled four groups of mice: WT-chow, WT-HFD, PPAR-γ-/--chow and PPAR-γ-/-- HFD. After 16 weeks
of treatment, mice were sacrificed for experimental measurements.

Hemodynamic and Echocardiographic measurement
Echocardiographic measurements were taken before and after 16 weeks of HFD treatment to
determine the baseline heart function and ventricular dimensions in the experimental groups. Cardiac
function and ventricular dimensions were calculated as described previously [49]. Briefly, following light
sedation with 1% Isoflurane, mice were placed on a platform in left lateral decubitus position for imaging.
All hairs were removed from chest area using chemical hair remover and aquasonic clear ultrasound gel
(Parker Laboratories, Fairfield, NJ) without bubbles was applied to the thorax surface to optimize the

1319

Physiol Biochem 2018;48:1317-1331
Cellular Physiology Cell
© 2018 The Author(s). Published by S. Karger AG, Basel
DOI: 10.1159/000492091
and Biochemistry Published online: July 26, 2018 www.karger.com/cpb
Sikder et al.: Ketogenesis in Type 2 Diabetes with Cardiac Dysfunction

visibility of the cardiac chambers. Echocardiography was done using Visualsonic Ultrasound System (Vevo
2100, Toronto, Canada) as described earlier [50]. Standard long axis M-Mode and PW droppler mode views
were recorded when the mouse possessed a target heart rate between 450 and 550 beats per minute.
Left ventricular (LV) mass, E/A ratio, and percent ejection fraction (%EF) and fractional shortening (% FS)
were calculated.

NRCM isolation and treatment
Cardiomyocytes were isolated from the ventricles of Sprague-Dawley rat pups using enzymatic
digestion [51]. Briefly, hearts were removed from 1-2 days old pups, digested in perfusion buffer containing
type II collagenase (Worthington Biochemical Corp., Lakewood, NJ) to dissociate ventricular myocytes. After
isolation, cells were pre-plated for 30 minutes to avoid non-myocyte populations. Then myocytes were
recollected and plated in collagen coated dishes (Sigma-Aldrich) at a density of 160, 000/cm2 in 10% calf
bovine serum (CBS) DMEM supplemented with 1 mmol/liter L-glutamine, antibiotic/antimycotic solution,
and 100 µmol/L 5-bromo-2-deoxyuridine (BrdU). The cells were maintained at 37 °C in 95% humidified
atmosphere, containing 5% CO2 concentration. Under these high density conditions, the myocytes form
cell-cell contacts and display spontaneous contractile activity within 24 hours of plating.
Caspase 3/7 apoptotic staining
Cells were kept in DMEM media supplemented with 10% calf bovine serum (CBS), 1 mmol/liter
L-glutamine, antibiotic/antimycotic solution and treated with different concentrations of D,L sodium-βHB
(Sigma-54965) (0.1-100 mM) for 12 hours, fixed with PFA and stained with caspase 3/7 kit (Thermo fisher,
PA, USA) and counterstained with DAPI.

Serum lipid profile
Total cholesterol (TC), free FAs and triglycerides (TG) were measured from serum using colorimetric
kits from Biovision (Milpitas, CA) according to the manufacturers’ protocol. Briefly, serum sample was
mixed with assay buffer and enzyme mix, incubated in dark and measured at 570 nm using a plate reader.
Quantification was done from standard curve using the corresponding standards for cholesterol, TG, or FA.
Serum Insulin
Serum insulin was measured using ELISA kit from Millipore (Billerica, MA, EZRMI-13K) according to
the manufacturers’ protocol.

Serum ketone body measurement:
Serum βOHB was measured using a colorimetric kit from Biovision (K632) according to the
manufacturer’s protocol. Briefly, serum sample was mixed with assay buffer and enzyme mix and substrate
mix, incubated and measured at 450 nm using a plate reader. Quantification was done from standard curve
using the corresponding standards.

Immunohistochemistry (IHC)
Tissues were fixed in 10% formalin, embedded in paraffin, and sectioned at 5 µm thickness. Paraffin
heart sections were deparaffinized in xylene and rehydrated. Antigen retrieval was achieved by boiling
the slides in citrate solution for 20 minutes and slides were then washed with phosphate-buffered Saline
(PBS). After quenching endogenous tissue peroxidase activity with 3% H2O2 for 15 minutes, slides were then
washed in PBS and blocked in PBS containing 2.5% serum at room temperature for 30 minutes. Primary
antibodies to detect PPAR-γ and HMGCS2 (Abcam, Cambridge, MA), or PDK4 (Thermo Fisher, Rockford,
IL) were applied overnight at 4°C in PBS containing 2.5% serum. The next day, samples were washed in
PBS and then sequentially incubated with Vectastain Elite ABC Kit (Avidin/Biotin/Horseradish PeroxidaseSystem (Vector Laboratories)). The peroxidase reaction was visualized using 3, 3’-diaminobenzidine
tetrahydrochloride (DAB) and slides were counterstained with hematoxylin.
Histopathology of the heart
Transverse section of heart containing both ventricles together from each mouse was cleaned,
processed and embedded in paraffin wax. Paraffin blocks were cut by rotary microtome at 5 µm thickness.
The sections processed and stained with hematoxylin and eosin for morphological evaluation of the heart
and with picrosirius red for collagen deposition. The stained slides were observed using a compound
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microscope (Nikon, USA) at 200x magnification. The photographs were analysed and quantified with ImageJ
software.

Oil-red-o staining
Fresh frozen heart sections (6 µm) were fixed on ice cold 10% formalin for 5-10 minutes, air dried
and treated with propylene glycol for few minutes. Stained in pre- warmed Oil Red O solution in 60 ºC oven
and differentiate in 85% propylene glycol for 2-5 mins. Rinse with distilled water and counter stained in
haematoxylin.
Immunoblot analysis
Extraction of proteins from heart tissue samples and NRCM was performed as described previously [49].
in brief, heart tissue was homogenised and cell lysates were obtained in FAK lysis buffer (50 mM Tris-HCl,
pH 7.5, 100 uM sodium pyrophosphate, 1 mM sodium fluoride, 150 mM NaCl, 0.1% SDS, 1% triton X-100, 0.5
mM EDTA) containing protease and phosphatase inhibitors. The lysates were obtained by centrifugation and
the supernatants were subjected to immunoblotting analysis according to the manufacturers’ instructions.
Each panel in each figure represents results from a single gel exposed for a uniform duration, with bands
detected by LI-COR Odyssey imaging system (LI-COR, Inc., Nebraska USA). PPAR-γ and HMGCS2 (Abcam,
Cambridge, MA). BDH1 and PDK4 (Thermofisher, Rockford, IL). Glut4 (Bioss, Woburn, MA), Bax, Histone 3,
Cytochrome c, and Bad (Cell Signaling Technology, Danvers, MA). GAPDH (Millipore, Billerica, MA).

Assessment of apoptosis by TUNEL assay
Determination of apoptosis was done from paraffin embedded LV section by DeadEnd™ Fluorometric
TUNEL assay kit (Promega, Madison, WI) according to the manufacturers’ protocol.
Quantitative real-time (qRT) PCR
Total RNA were extracted from LV tissue with TRIZOL. cDNA was generated from 2µg of total RNA
using High Capacity RNA-to-cDNA kit (Life Technology Grand Island, NY) according to the manufacturer’s
instruction. qRT-PCR assays were performed using PerfeCT Super Green Super Mix (Quanta Biosciences,
Beverly, MA) by using specific primers PPAR-γ, HMGCS2, BDH1 and PDK4 (Invitrogen, Carlsbad, CA)
Differences in expression were determined by the relative quantification method; the cycle threshold (CT)
values of the target genes were first normalized to the CT values of endogenous control GAPDH. All primer
sequences are given in Table 1.
PPAR-γ retrovirus preparation and infection
The MSCV-IRES-GFP retrovirus vector and the vector pSV-ψ-E-MLV that provides ecotropic packaging
helper function and infection methods were described previously [52, 53]. Retroviruses were prepared by
transient co-transfection of vector expressing PPAR-γ, PγCA and empty vector together with the helper viral
vector into 293T cells, using calcium phosphate precipitation. The retroviral supernatants were harvested
48 h after transfection and filtered through a 0.45 µm filter. NRCMs were incubated with fresh retroviral
supernatants in the presence of 5 µg/ml polybrene for 24 h, cultured for a further 48 hrs, and subjected to
western blot analysis.

Data analysis
All values recorded are expressed as the mean ± standard error of the mean. Statistical analysis, such
as one-way ANOVA followed by post hoc analysis, was done using Graph pad version 4.0 software (San
Diego, CA, USA). A value of *p < 0.05 (denoted as *chow vs HFD, # WT-HFD vs PPAR-/--HFD) was considered
significant.

Results

Chronic HFD consumption causes systemic
hyperglycemia and hyperlipidemia
To examine the contribution of HFD on body
weight, blood glucose and blood lipid levels, WT
mice were fed with 60% HFD for 16 weeks. Body
weight and blood glucose levels were progressively

Table 1. List of Primer sequence used for
qRT PCR
Gene
Forward (5’-3’)
Reverse (5-3’)
HMGCS2 CCGTATGGGCTTCTGTTCAG
AGCTTTGTGGGTTCCATCA
PDK4 CAAAGACGGGAAACCCAAGCC CGCAGAGCATCTTTGCACAC
BDH1
GAATTCAGCCTGCCGGTTTG TGCATCCCGCTGTCAGGTAA
PPAR-y GCCCTTTGGTGACTTTATGGA GCAGCAAGGTTGTCTTGGATG
GAPDH
GGCAAATTCAACGGCACA
GTTAGTGGGGTCTCGCTCTG
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and significantly increased during the experimental period in HFD-WT mice compared to WTchow mice (Fig. 1A & 1B). Impaired glucose tolerance and diminished insulin responsiveness
were evident in HFD-mice from their respective patterns of glucose and insulin tolerance
curves (Fig. 1C & 1D). The insulin resistance was further confirmed by an 8.5 fold increase
in serum insulin level in WT- HFD group over its counterpart (Fig. 1E). High body weight
and hyperglycemia were correlated with high levels of blood cholesterol and free FAs in
HFD-mice. Total Cholesterol (TC) and total free FAs were increased by 2.1 fold and 3.6 fold,
respectively in WT-HFD compared to WT-chow group (Fig. 1F & 1G). Oil-red-O staining
showed that lipid deposition in LV heart of WT-HFD group was more than 2 fold higher than
in the LV heart WT-chow group (Fig. 1H & 1I).

HFD-mediated T2DM leads to ventricular hypertrophy and induced cardiac dysfunction
To determine the effect of prolonged HFD treatment on cardiac physiology, heart weight
and tibia length were measured during the sacrifice. Heart weight was increased by 35% and
tibia length/heart weight ratio was increased by 20% in WT-HFD group compared to chow,
indicating cardiac hypertrophy in WT-HFD group (Fig. 2A & 2B).
To determine the impact of HFD-mediated T2DM on cardiac function, we performed
echocardiography after 16 weeks of treatmentFigure
(Fig.
2C-2H). Compared with WT-chow mice,
1
the WT-HFD mice had significant reduction
in LV ejection fraction (EF), LV fractional
shortening (FS), and E/A ratio (Fig. 2C, 2D,
2H). Additionally, the LV internal diameter
diastole dimension (LVID;d), LV internal
diameter systole (LVID;s), and LV posterior
wall thickness (LVPW;d) were increased
significantly in the WT-HFD group compared
to the WT-chow group (Fig. 2E-2G).
Ketone bodies play a crucial role in HFDmediated cardiomyocyte lipotoxicity
In order to validate our findings from
microarray data (data not shown), we
performed qPCR and immunoblot to check
the expression at the mRNA and protein
levels of three mitochondrial metabolic
enzymes: HMGCS2, BDH1 and PDK4 (Fig.
3A-3C). Expression mRNA of HMGCS2,
BDH1, and PDK4 was increased by 3.3
fold, 1.7 fold and 2.3 fold, respectively
in WT-HFD group compared to chow
group (Fig. 3A). The protein expression
of these enzymes was also significantly
increased in WT-HFD group compared to
WT-chow group (Fig. 3B & 3C). HFD mice
also experienced a dramatic rise in serum
βOHB concentrations (100% increase)
over control (Fig. 3D). The overexpressed
ketogenic enzymes were reflected in very
high levels of ketone bodies in the blood
due to chronic HFD induction.
To determine whether ketone bodies
are sufficiently toxic to induce apoptosis,
we treated NRCMs with βOHB at different
concentrations. We found that apoptosis
started from as low as 1mM concentration

Fig. 1. Chronic HFD consumption causes systemic
hyperglycemia and hyperlipidemia. (A) Body weight
(BW); (B) Blood glucose (BG); (C) Glucose tolerance
test (GTT); (D) Insulin tolerance test (ITT), (E) Serum
insulin, (F) Serum total cholesterol (TC), (G) Serum
free fatty acids (FFA) in chow and HFD C57BL/6
treated mice. Oil-red- O staining of LV heart (H) and
its quantification (I) in chow and HFD mice (*p<0.05
vs chow).
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Fig. 2. HFD-mediated T2D leads ventricular
hypertrophy and induced cardiac dysfunction.
(A) Heart weight (HW), (B) Heart weight/Tibia
length (HW/TL) ratio in chow and HFD mice.
Echocardiographic analysis of (C) left ventricular
(LV) fractional shortening (FS), (D) LV Ejection
Fraction (EF), (E) Left ventricular posterior wall end
diastole (LVPW;d), (F) left ventricle internal diameter,
diastole (LVID;d), (G) left ventricle internal diameter,
systole (LVID;s) and (H) E/A ratio in control and HFD
treated mice (*p<0.05 vs chow).

Fig. 3. HFD-mediated T2D leads to cardiomyocyte
lipotoxicity via ketone body synthesis. (A) qRT-PCR
expressions of HMGCS2, BDH1, and PDK4 mRNAs
from LV heart in bar diagram normalized with
GAPDH internal control in chow and HFD group. (BC) Immunoblot expression of HMGCS2, BDH1, and
PDK4 proteins from LV heart and their quantification
normalized with GAPDH control in chow and HFD
group. (D) Serum levels of β-hydroxy butyrate (β-HB)
in chow and HFD mice. (E-F) Caspase 3/7 staining in
Neonatal rat cardiomyocytes treated with different
concentrations of βHB and their quantification.
(*p<0.05 vs chow and vs control).

Figure 2

Figure 3

and by 100 mM concentration most of the myocyte populations were apoptotic. 10 mM
concentration was found to be the LD50 for βOHB treatment to the myocytes (Fig. 3E & 3F).

HFD-mediated T2DM leads to activation and nuclear translocation of PPAR-γ
As a regulatory factor for lipid metabolism and adipogenesis [39], next we determined
the expression of PPAR-γ in LV heart by qPCR and IHC. We found almost 2 fold increase in
mRNA expression of PPAR-γ in the HFD-WT LV heart compared to the chow-WT LV heart
(Fig. 4A). Quantification of IHC data revealed over 5 fold increase in PPAR-γ positive cells in
HFD-LV heart compared to its control (Fig. 4B & 4C).
In order to check the nuclear translocation upon activation, next we checked the
expression of PPAR-γ both from nuclear and cytosolic extracts. We found a significant
increase in nuclear expression of PPAR-γ in WT-HFD group compared to control but no
difference was observed in its cytosolic expression (Fig. 4D & 4E). This data confirms the
nuclear translocation of PPAR-γ after T2DM induction by HFD.
PPAR-γ activation by HFD upregulates the expression of HMGCS2, BDH1 and PDK4
Immunoprecipitation (IP) from LV heart tissues lysates of HFD animals with specific
PPAR-γ antibody followed by an immunoblot with specific antibodies to HMGCS2, BDH1, and
PDK4 individually showed positive correlation between PPAR-γ HMGCS2, BDH1 and PDK4
as compared to control hearts (Fig. 5A & 5B).
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Fig. 4. HFD-mediated T2D stimulate leads to
activation and nuclear translocation of PPAR-γ. (A)
qRT-PCR expression of PPAR-γ mRNA from LV heart
in bar diagram normalized with GAPDH internal
control in chow and HFD group. (B-C) PPAR-γ
immunostaining and its quantification from LV
heart in chow and HFD group. (D-E) Immunoblot
showing nuclear and cytosolic expressions of PPAR-γ
in chow an HFD group from LV heart extracts and
their quantifications normalized with Histone3
and GAPDH for nuclear and cytosolic fractions,
respectively (*p<0.05 vs chow).

Figure 4

Figure 5

Fig. 5. PPAR-γ interacts with and upregulates
HMGCS2, BDH1 and PDK4 expressions. (A-B) Coimmunoprecipitation of PPAR-γ with its downstream
molecules HMGCS2, BDH1 and PDK4 from LV heart
followed by immunoblot in chow and HFD mice
and their quantifications (*p<0.05 vs chow). (C-D)
Neonatal rat cardiomyocytes (NRCMs) treated with
Rosiglitazone and G3335 in the presence of Palmitic
acid (PA; 300µM) or Oleic acid (OA; 300µM) for 12h
followed by immunoblot for PPAR-γ, HMGCS2, BDH1,
and PDK4 and their quantifications represented
by bar diagrams normalized with GAPDH (*p<0.05
vs OA control). (E-F) NRCMs infected with PPAR-γ
adenovirus or Lac-Z control and treated with
PA for 12h followed by immunoblot for PPAR-γ,
HMGCS2, BDH1, and PDK4 and their quantifications
represented by bar diagrams normalized with
GAPDH (*p<0.05 vs chow, or control or Lac Z control).

Next, we translated the in vivo IP findings to in vitro primary culture. Treatment of NRCMs
with rosiglitazone, a PPAR-γ agonist, enhances the expressions of HMGCS2, BDH1, and PDK4
consistently in the presence of PA, indicating a positive correlation between PPAR-γ and these
mitochondrial enzymes (Fig. 5C and 5D). PPAR-γ antagonist G3335 treated cells showed
significantly prevented the increase of all three concerned metabolic enzymes HMGCS2,
BDH1 and PDK4 over the baseline. To gain insight into the role of PPAR-γ in mitochondrial
enzyme expression, we conducted gain- of-function experiment in which we transduced
NRCMs with carrying wild-type PPAR-γ (WT-PPAR-γ) in the presence of palmitate. PPAR-γ
overexpression showed a significant increase in the expressions of HMGCS2, BDH1, and PDK
compared with lacZ control (Fig. 5E & 5F), confirming that activation of PPAR-γ is directly
responsible for enhanced responsiveness of these mitochondrial metabolic enzymes.
PPAR-γ ablation downregulates the expression of HMGCS2, BDH1, and PDK4 in the diabetic
LV heart
To explore the functional effects associated with PPAR-γ in vivo, PPAR-γ-/- and their WT
controls were subjected to HFD treatment. Relative to HFD-WT samples, PPAR-γ-
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diabetic heart showed a significant decrease in the levels of HMGCS2, BDH1, and PDK4
expression (Fig. 6A & 6B). IHC of diabetic LV heart showed similar results as immunoblot
analysis. Fig. 6C-6E shows increased HMGCS2 and PDK4 immunostaining in HFD-WT hearts
compared with chow-WT hearts. PPAR-γ ablation in diabetic mice significantly attenuated
the expressions of the HMGCS2 and PDK4 enzymes compared to WT-HFD group (Fig. 6C-6E).
BDH1 expression was also significantly decreased in PPAR-γ-/- diabetic hearts compared to
WT diabetic group (data not shown).
PPAR-γ ablation ameliorates HFD-mediated hyperlipidemic and diabetic changes
PPAR-γ-/- mice maintained a low level of body weight and blood glucose level throughout
the experimental period. Final body weight was 20% lower and blood glucose was 30%
lower in the PPAR-γ-/--HFD mice compared to the WT-HFD group (Fig. 7A & 7B). Glucose
tolerance and insulin responsiveness were also significantly improved in PPAR-γ-/--HFD
mice compared to the WT-HFD mice, based on their respective glucose tolerance and insulin
tolerance results (Fig. 7C & 7D). Although the food intake and calorie intake were comparable
in both WT-HFD and PPAR-γ-/--HFD animals (Fig. 7E-7F), the storage body fat (both visceral
and subcutaneous) were found to be significantly high in WT-HFD compared to its chow
counterpart. Interestingly,
PPAR-γ-/--HFD animals significantly ameliorated body fat
storage compared to WT-HFD animals as described in figure 7G. The reduced glucose uptake
and its utilization in the WT-HFD group was evident from a significant inhibition in glut4
receptor expression compared to WT-Chow and PPAR-γ-/- animals (Fig.7H & 7I).
Attenuation in blood glucose level and insulin responsiveness was reflected in the lipid
profile. TC and free FA levels were significantly reduced (64% and 38%) in the PPAR-γ-/-HFD mice compared to WT-HFD mice (Fig. 7J & 7K). Serum levels of TG and its tissue
deposition were also remarkably deceased (53% and 63%) after PPAR-γ ablation even with
HFD treatment (Fig. 7L-7N).
/-

PPAR-γ deletion restores HFD-mediated changes in cardiac function and prevents
apoptosis
Recently, PPAR-γ deletion was found to prevent lipotoxicity in heart [54]. Herein, we
found that PPAR-γ deletion recovers cardiac functions in HFD group. FS, EF, and E/A ratio
were significantly restored in the PPAR-γ-/--HFD mice compared to the WT-HFD mice (Fig.
8A & 8C). PPAR-γ deletion did not affect the LVID;d, LVID;s, and LVPW;d in the control group;
however, it significantly suppressed the increase in these parameters in the diabetic group
compared to HFD-WT mice (Fig. 8B). Next, we analyzed total collagen content in the mice
Fig. 6. PPAR-γ ablation downregulates the expression
of HMGCS2, BDH1 and PDK4 in the diabetic heart.
(A-B) Immunoblot showing expressions of PPAR-γ,
HMGCS2, BDH1, and PDK4 from LV heart and their
quantification with bar diagrams normalized with
GAPDH in WT and PPAR-γ-/- mice fed with chow
or HFD. (C-E) Immunostaining with HMGCS2, and
PDK4 in paraffin embedded LV heart and their
quantifications in WT and PPAR-γ-/- mice fed with
chow or HFD (*p<0.05 chow vs HFD, #p<0.05 WTHFD vs PPAR-/--HFD).

Figure 6
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Fig. 7. PPAR-γ ablation ameliorates
HFD-mediated hyperlipidemic and
diabetic changes. Periodic change
in (A) BW; (B) BG levels in WT and
PPAR-γ-/- mice fed with chow or
HFD. (C) Glucose test tolerance;
(D) Insulin test tolerance in WTHFD and PPAR-γ-/-- HFD mice.
(E-F) Cumulative food intake and
calorie intake over time among the
experimental groups. (G) Storage
body fat composition among
WT and PPAR-γ-/- . (H-I) Glut4
expression and its quantification
from LV heart normalized with
GAPDH in WT and PPAR-γ-/- mice
fed with chow or HFD. Serum levels
of (J) TC; (K) FFA; and (L) TG in WT
and PPAR-γ-/- mice fed with chow
or HFD. (M-N) Oil-red-O staining
of LV heart and its quantification
in WT and PPAR-γ-/- mice fed with
chow or HFD (*p<0.05 chow vs
HFD, #p<0.05 WT-HFD vs PPAR-/-HFD).

Figure 7

hearts because collagen deposition influences the passive mechanical properties of the
myocardium and then affects the cardiac performance. WT-HFD heart showed high levels of
fibrosis, as revealed by collagen deposition from picrosirius red staining and PPAR-γ ablation
significantly alleviated this diabetic-induced cardiac fibrosis (Fig. 8D & 8E).
To further confirm that PPAR-γ has a protective role after diabetes induction, we analyzed
the degree of apoptotic cell death with TUNEL staining. We found 3 fold more TUNEL positive
cells in the LV heart of WT-HFD group compared to WT-chow group, indication of apoptosis
and cell death. PPAR-γ ablation significantly diminished apoptotic changes in the WT-HFD
group (Fig. 8F & 8G). Protein expression of 3 major apoptotic markers (i.e., cyt-c, bax, bad)
was significantly upregulated by chronic HFD treatment in WT mice (2 fold, 2.5 fold, and
1.7 fold, respectively). However, PPAR-γ deletion significantly prevented the upregulation of
these apoptotic molecules. Collectively, these data show that PPAR-γ deletion offers cardioprotection in response to HFD treatment (Fig. 8H & 8I).
Discussion

In this present study, the impact of chronic HFD treatment on diabetes and cardiac
health was investigated from a metabolic approach in terms of lipotoxicity. HFD intake for a
chronic term is one of the major underlying factors for T2DM which plays a critical role in the
development of the complex phenotype of the cardiac hypertrophy, ventricular dilatation
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Fig.
8. PPAR-γ deletion restores
HFD-mediated
changes
in
cardiac
function and prevents apoptosis. (A-C)
Echocardiographic data showing LVFS,
LVEF, LVPWd, LVIDd, LVIDs, and E/A
ratio in M-mode in WT and PPAR-γ-/mice fed with chow or HFD. (D) Collagen
deposition with Picrosirius red (200x) in
paraffin embedded LV heart in WT and
PPAR-γ-/- mice fed with chow or HFD.
(E) Semiquantitative analysis of collagen
deposition was done by a computer
imaging system. (F & G) Apoptotic TUNEL
staining (200x) from LV heart and its
quantification in WT and PPAR-γ-/- mice fed
with chow or HFD. (H-I) Immunoblot from
LV heart showing expressions of apoptotic
molecules Cytochrome-c, Bax and Bad
followed by quantification normalized
with GAPDH in WT and PPAR-γ-/- mice fed
with chow or HFD (*p<0.05 chow vs HFD,
#
p<0.05 WT-HFD vs PPAR-/--HFD)

Figure 8

and heart failure [8-10]. Being such an organ that primarily uses lipids as a source of energy,
heart is more susceptible against lipotoxicity in long-term exposure to high levels of lipids
[8, 10]. The pathological pathways and the underline cellular entities linking cellular lipids
to cardiac dysfunction are obscure. Our objective was to determine whether HFD induced
T2DM was linked to activate mitochondrial ketogenic enzymes via enhanced PPAR-γ nuclear
translocation. To investigate the impact of PPAR-γ on T2DM and cardiac dysfunction, we
used PPAR-γ-/- mice against chronic HFD treatment and compared the findings with that of
the WT mice. In this study we demonstrated for the first time by performing a cross of CREERT2-PPAR-γ onto the PPAR-γ –/– background, how the T2DM and cardiac dysfunction can be
rescued after prolonged HFD induction.
In the present study, HFD treatment for 16 weeks was found to be associated with
increased body weight, blood glucose, TC and FA levels. We also found there was lipid
accumulation in the LV tissue in WT-HFD mice. At the same time there were significant
reductions in glucose tolerance and insulin responsiveness. These findings established
the previous reports about the link between HFD intake, obesity and T2DM [55, 56].
Echocardiography findings depicted how the cardiac functions were compromised in WTHFD group with significantly altered contractile parameters compared to WT-chow mice.
These outcomes support the preceding findings that reduced cardiac function is associated
with increased lipids found in patients with obesity and diabetes [55, 57].
Cardiac muscle is the most energy-requiring tissue in the body and primarily uses FAs
and in condition such as glucose intolerance and insulin unresponsiveness created by HFDdriven T2DM, it relies more to lipid-derived FAs [58]. To investigate if cardiac toxicity in
diabetic mice is associated with defective mitochondrial function, we found upregulation
of ketogenic enzymes HMGCS2 and BDH1 and at the same time upregulation of PDK4 that
regulates FAO enzymes, both at mRNA and protein levels in WT-HFD mice over control.
As a consequence, the serum ketone body level was also found to be significantly high in
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WT-HFD group compared to WT-chow. To check the cytotoxic effects of the ketone bodies
we found when cardiomyocytes were treated in vitro with βOHB, one of the major ketone
bodies produced by the above mentioned mitochondrial enzymes, majority of the cells die
within 12 hours’ time period with a LD50 value as low as 10 mM. PPARs are transcription
factors that function as important regulators of cell differentiation and energy homeostasis.
Among the 3 subtypes, PPAR-γ acts as an adipogenic factor that regulates the expression
of genes associated with lipid metabolism [39]. We also checked the expressions of all 3
members of the PPAR family in WT-Chow and WT-HFD heart (data not shown) both at gene
and protein levels. Interestingly, only PPAR-γ subtype was expressed considerably after HFD
induction in LV heart tissue. Not only we saw an overexpression of PPAR-γ in whole tissue
extract but there was significantly high PPAR-γ level in the nuclear fraction compared to
the cytosolic fraction, demonstrating activation and nuclear translocation of PPAR-γ induced
by high concentration of intracellular lipids. This PPAR-γ overexpression in HFD-treated
heart substantiates the finding of Mafella et al, where they showed hearts of patients having
greater lipid accumulation also have increased expression of PPAR-γ [59].
Inside the nucleus, PPAR-γ binds to the PPRE in the promoter region of target genes
[39, 45, 46] and modifies their expressions. However, we demonstrated for the first
time that PPAR-γ activation directly associated to upregulation of HMGCS2, PDK4 and BDH1
which was not shown before. We verified this association in LV tissue by IP. Also this data was
validated by in vitro study where we treated the cells with PPAR-γ agonist (rosiglitazone) or
antagonist (G3335) and found reciprocal changes in the expressions of HMGCS2, BDH1 and
PDK4 with changes in PPAR-γ expression. Additionally, we found over expressions of the
above-mentioned mitochondrial enzymes when cardiomyocytes were infected with PPAR-γ
adenovirus.
Findings with WT-HFD mice were reciprocated in PPAR-γ-/- animals. In PPAR-γ-/--HFD
mice heart, we found downregulation of HMGCS2, BDH1 and PDK4 expressions from their
corresponding immunoblots and IHC as anticipated. PPAR-γ-/--HFD animals prevented
escalation in body weight, blood glucose and lipid levels compared to WT- HFD. The former
group showed improved glucose tolerance and insulin responsiveness reflected by their
respective tolerance curves. The above set of data indicates prevention in hyperlipidemia
and consequent T2DM in PPAR-γ-/- -HFD animals compared to WT-HFD. Improvements in
cardiac contractile and prevention in fibrotic development in PPAR-γ-/--HFD heart over its
WT counterpart obviously suggest better cardiac structural and functional health which is
supported by the fact that PPAR-γ-/-- HFD animals also had diminished TUNEL positive cells
and a reciprocal reduction in pro-apoptotic molecules expression in LV heart compared to
WT-HFD.
In summary, we present data that shows for the first time: 1) HFD mediated activation
of PPAR-γ is directly associated with HMGCS2, BDH1 and PDK4 upregulation both in vivo
and in vitro systems, 2) PPAR-γ mediated metabolic anomalies are directly responsible for
the generation of T2DM and cardiac dysfunction which can be prevented by PPAR-γ ablation
approach.
These findings provide important information regarding the impact of PPAR-γ in
lipotoxic T2DM during the development of heart failure and provide new rationale for
treatment strategies aimed at PPAR-γ antagonism. These results have led us to hypothesize
that PPAR-γ antagonists might be useful in treatment of patients having metabolic diabetes
and cardiac complications.
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